Antengene Corporation Limited

6996

KYG039571008

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:35 2024-04-19 am EDT			5-day change	1st Jan Change
0.83 ^HKD	-3.49%		-12.63%	-58.50%

Mar. 22	Antengene Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 20	Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study	CI

Antengene Corporation Limited(SEHK:6996) added to S&P Global BMI Index

June 21, 2021 at 12:00 am EDT

Latest news about Antengene Corporation Limited

Antengene Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study	Mar. 20	CI
Antengene's Myeloma Medication Included in China's National Reimbursement Drug List	Dec. 13	MT
Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance	Dec. 13	CI
Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States	Dec. 10	CI
Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma	Dec. 06	CI
Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day	Nov. 16	CI
Antengene Corporation Limited Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031	23-09-21	CI
Antengene Unaware of Reasons Behind Recent Share Price Drop, Surge in Trade Volume	23-09-18	MT
Antengene Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Hansoh, Antengene Join Forces for Anti-Tumor Tablet Commercialization in China; Antengene Shares Rise 4%	23-08-10	MT
Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China	23-08-10	CI
Hong Kong Regulator Gives Go Ahead to Antengene’s Application for Multiple Myeloma Drug	23-07-18	MT
Antengene Says Hong Kong Approves Myeloma Drug	23-07-18	MT
Antengene Corporation Limited Announces Xpovio Regulatory Approval in Hong Kong for the Treatment of Relapsed And/Or Refractory Multiple Myeloma	23-07-16	CI
Antengene Announces Xpovio Plus Bortezomib and Dexamethasone Included for Reimbursement by the Pbs in Australia for the Treatment of Relapsed And/Or Refractory Multiple Myeloma	23-05-31	CI
Antengene Corporation Limited Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers	23-05-23	CI
Antengene Corporation Limited Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031	23-05-17	CI
US FDA Clears Perform Trial for Antengene's Tumor Treatment	23-05-17	MT
Antengene Announces Five Presentations At the 2023 American Association for Cancer Research Meeting	23-04-17	CI
Antengene Corporation Limited Announces Board Changes	23-04-14	CI
Antengene Shrinks Loss in 2022 as Revenue Jumps Nearly Sixfold	23-03-28	MT
Antengene Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
Antengene Obtains China Approval for Phase I Study of Tumor Treatment	23-03-13	MT
Antengene Corporation Limited Announces Approval for the Phase I Clinch Trial of ATG-022	23-03-13	CI

Chart Antengene Corporation Limited

Duration

Period

More charts

Antengene Corporation Limited is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.

Sector

Biotechnology & Medical Research

Calendar

2024-08-15 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Antengene Corporation Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.7672 CNY

Average target price

1.666 CNY

Spread / Average Target

+117.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ANTENGENE CORPORATION LIMITED	-58.50%	74.12M
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.75%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-28.19%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.33B
SAREPTA THERAPEUTICS, INC.	+19.90%	10.94B

Bio Therapeutic Drugs